Chemotherapy plus immunotherapy and radiation for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy before a shorter course of radiation helps older or less fit patients with stage III lung cancer. It aims to improve treatment results while being more manageable for patients who might not tolerate standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage III non-small cell lung cancer that cannot be removed with surgery.
- You must be considered 'unfit' for standard treatment, for example because you are 70 or older or have other health problems.
- You must be able to have chemotherapy and radiation therapy, as decided by your doctors.
- Your breathing, blood counts, and kidney and liver function must be within certain limits.
- You must not have had previous immunotherapy or chemotherapy for your lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Stage III NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.